|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US5128257A
(en)
|
1987-08-31 |
1992-07-07 |
Baer Bradford W |
Electroporation apparatus and process
|
|
DE68925030T2
(de)
|
1988-01-21 |
1996-07-25 |
Massachusetts Inst Technology |
Molekültransport durch gewebe mit der verwendung von elektroporation.
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
US5089261A
(en)
|
1989-01-23 |
1992-02-18 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
|
CA2019758C
(en)
|
1990-06-25 |
2001-09-04 |
Kevin L. Firth |
Improved electroporation device and method
|
|
US5137817A
(en)
|
1990-10-05 |
1992-08-11 |
Amoco Corporation |
Apparatus and method for electroporation
|
|
US5173158A
(en)
|
1991-07-22 |
1992-12-22 |
Schmukler Robert E |
Apparatus and methods for electroporation and electrofusion
|
|
US5304120A
(en)
|
1992-07-01 |
1994-04-19 |
Btx Inc. |
Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
|
|
US5273525A
(en)
|
1992-08-13 |
1993-12-28 |
Btx Inc. |
Injection and electroporation apparatus for drug and gene delivery
|
|
US5318514A
(en)
|
1992-08-17 |
1994-06-07 |
Btx, Inc. |
Applicator for the electroporation of drugs and genes into surface cells
|
|
PT672141E
(pt)
|
1992-10-23 |
2003-09-30 |
Immunex Corp |
Metodos de preparacao de proteinas oligomericas soluveis
|
|
GB9317380D0
(en)
|
1993-08-20 |
1993-10-06 |
Therexsys Ltd |
Transfection process
|
|
US5821332A
(en)
|
1993-11-03 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor on the surface of activated CD4+ T-cells: ACT-4
|
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
|
US5691188A
(en)
|
1994-02-14 |
1997-11-25 |
American Cyanamid Company |
Transformed yeast cells expressing heterologous G-protein coupled receptor
|
|
WO1996000295A1
(en)
|
1994-06-27 |
1996-01-04 |
The Johns Hopkins University |
Targeted gene delivery system
|
|
US5908635A
(en)
|
1994-08-05 |
1999-06-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method for the liposomal delivery of nucleic acids
|
|
US5484720A
(en)
|
1994-09-08 |
1996-01-16 |
Genentech, Inc. |
Methods for calcium phosphate transfection
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
DE69624436T2
(de)
|
1995-04-08 |
2003-08-28 |
Lg Chemical Ltd., Seoul/Soul |
Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
US6010613A
(en)
|
1995-12-08 |
2000-01-04 |
Cyto Pulse Sciences, Inc. |
Method of treating materials with pulsed electrical fields
|
|
IL129138A0
(en)
|
1996-10-11 |
2000-02-17 |
Bristol Myers Squibb Co |
Methods and compositions for immunomodulation
|
|
DK0973928T3
(da)
|
1997-03-11 |
2010-08-09 |
Univ Minnesota |
DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
|
|
GB9710809D0
(en)
|
1997-05-23 |
1997-07-23 |
Medical Res Council |
Nucleic acid binding proteins
|
|
US6475994B2
(en)
|
1998-01-07 |
2002-11-05 |
Donald A. Tomalia |
Method and articles for transfection of genetic material
|
|
US6312700B1
(en)
|
1998-02-24 |
2001-11-06 |
Andrew D. Weinberg |
Method for enhancing an antigen specific immune response with OX-40L
|
|
DE69942334D1
(de)
|
1998-03-02 |
2010-06-17 |
Massachusetts Inst Technology |
Poly-zinkfinger-proteine mit verbesserten linkern
|
|
US6534261B1
(en)
|
1999-01-12 |
2003-03-18 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
US7013219B2
(en)
|
1999-01-12 |
2006-03-14 |
Sangamo Biosciences, Inc. |
Regulation of endogenous gene expression in cells using zinc finger proteins
|
|
AU2982900A
(en)
|
1999-02-03 |
2000-08-25 |
Children's Medical Center Corporation |
Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
|
|
US20030104526A1
(en)
|
1999-03-24 |
2003-06-05 |
Qiang Liu |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US6794136B1
(en)
|
2000-11-20 |
2004-09-21 |
Sangamo Biosciences, Inc. |
Iterative optimization in the design of binding proteins
|
|
US7030215B2
(en)
|
1999-03-24 |
2006-04-18 |
Sangamo Biosciences, Inc. |
Position dependent recognition of GNN nucleotide triplets by zinc fingers
|
|
US7189705B2
(en)
|
2000-04-20 |
2007-03-13 |
The University Of British Columbia |
Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
|
|
US6627442B1
(en)
|
2000-08-31 |
2003-09-30 |
Virxsys Corporation |
Methods for stable transduction of cells with hiv-derived viral vectors
|
|
EP2316490A3
(en)
|
2000-10-31 |
2012-02-01 |
PR Pharmaceuticals, Inc. |
Methods and compositions for enhanced delivery of bioactive molecules
|
|
ES2295639T3
(es)
|
2002-06-13 |
2008-04-16 |
Crucell Holland B.V. |
Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
|
|
JP2006500921A
(ja)
|
2002-07-30 |
2006-01-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
ヒト４−１ｂｂに対するヒト化抗体
|
|
US8034334B2
(en)
|
2002-09-06 |
2011-10-11 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
|
|
ITMI20022118A1
(it)
|
2002-10-04 |
2004-04-05 |
Abiogen Pharma Spa |
Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo.
|
|
CN101120083B
(zh)
|
2003-10-08 |
2013-03-27 |
威尔森沃尔夫制造公司 |
利用透气性材料进行细胞培养的方法及装置
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
CN101072578A
(zh)
|
2004-10-29 |
2007-11-14 |
南加州大学 |
用共刺激分子的联合癌症免疫疗法
|
|
EP1877090B1
(en)
|
2005-05-06 |
2014-01-15 |
Providence Health System |
Trimeric ox40-immunoglobulin fusion protein and methods of use
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
TWI466269B
(zh)
|
2006-07-14 |
2014-12-21 |
Semiconductor Energy Lab |
非揮發性記憶體
|
|
EP1894940A1
(en)
|
2006-08-28 |
2008-03-05 |
Apogenix GmbH |
TNF superfamily fusion proteins
|
|
KR20100014588A
(ko)
|
2007-02-27 |
2010-02-10 |
제넨테크, 인크. |
길항제 ｏｘ40 항체 및 염증성 및 자가면역 질환의 치료에서의 이의 용도
|
|
EP2484691B1
(en)
|
2007-07-10 |
2016-01-13 |
Apogenix GmbH |
TNF superfamily collectin fusion proteins
|
|
WO2009040789A2
(en)
|
2007-09-24 |
2009-04-02 |
Technion Research & Development Foundation Ltd. |
T cell subpopulations capable of treating cancer
|
|
SI2242771T1
(sl)
|
2007-12-14 |
2013-09-30 |
Bristol-Myers Squibb Company |
Vezane molekule k humanemu ox40 receptorju
|
|
EP2310409A2
(en)
|
2008-06-17 |
2011-04-20 |
Apogenix GmbH |
Multimeric tnf receptors
|
|
PL2604693T3
(pl)
|
2008-07-21 |
2016-09-30 |
|
Jednołańcuchowe cząsteczki TNFSF
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
WO2010078966A1
(en)
|
2009-01-09 |
2010-07-15 |
Apogenix Gmbh |
Fusion proteins forming trimers
|
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
US20130115617A1
(en)
|
2009-12-08 |
2013-05-09 |
John R. Wilson |
Methods of cell culture for adoptive cell therapy
|
|
WO2011072088A2
(en)
|
2009-12-08 |
2011-06-16 |
Wilson Wolf Manufacturing Corporation |
Improved methods of cell culture for adoptive cell therapy
|
|
AU2011256838B2
(en)
|
2010-05-17 |
2014-10-09 |
Sangamo Therapeutics, Inc. |
Novel DNA-binding proteins and uses thereof
|
|
WO2011159369A1
(en)
|
2010-06-14 |
2011-12-22 |
Iowa State University Research Foundation, Inc. |
Nuclease activity of tal effector and foki fusion protein
|
|
LT2609118T
(lt)
|
2010-08-23 |
2017-04-25 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antikūnai ir jų panaudojimo būdai
|
|
NZ729044A
(en)
|
2010-09-09 |
2020-07-31 |
Pfizer |
4-1bb binding molecules
|
|
US8962804B2
(en)
|
2010-10-08 |
2015-02-24 |
City Of Hope |
Meditopes and meditope-binding antibodies and uses thereof
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
US8673557B2
(en)
|
2011-02-28 |
2014-03-18 |
Seattle Children's Research Institute |
Coupling endonucleases with end-processing enzymes drives high efficiency gene disruption
|
|
US20120244133A1
(en)
|
2011-03-22 |
2012-09-27 |
The United States of America, as represented by the Secretary, Department of Health and |
Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
|
|
US20140115726A1
(en)
|
2011-04-05 |
2014-04-24 |
Cellectis |
New tale-protein scaffolds and uses thereof
|
|
WO2012177788A1
(en)
|
2011-06-20 |
2012-12-27 |
La Jolla Institute For Allergy And Immunology |
Modulators of 4-1bb and immune responses
|
|
JP6038920B2
(ja)
|
2011-08-23 |
2016-12-07 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
抗ｏｘ４０抗体およびそれを使用する方法
|
|
KR20140060541A
(ko)
|
2011-09-16 |
2014-05-20 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암을 치료하기 위한 rna 조작된 t 세포
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
US9315774B2
(en)
|
2011-10-21 |
2016-04-19 |
Cell Medica Limited |
Device for the aseptic expansion of cells
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
CN104379727A
(zh)
|
2012-05-18 |
2015-02-25 |
威尔逊沃夫制造公司 |
改进的用于过继细胞治疗的细胞培养方法
|
|
SG10201806573TA
(en)
|
2012-05-25 |
2018-09-27 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
US10815500B2
(en)
|
2012-06-05 |
2020-10-27 |
Cellectis |
Transcription activator-like effector (TALE) fusion protein
|
|
CN110241086A
(zh)
|
2012-06-11 |
2019-09-17 |
威尔逊沃夫制造公司 |
用于过继细胞疗法的改进的细胞培养方法
|
|
MX380562B
(es)
|
2012-12-12 |
2025-03-12 |
Broad Inst Inc |
Modificaciones de sistemas, métodos y composiciones guía optimizadas para la manipulación de secuencias.
|
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
|
PT2931898E
(pt)
|
2012-12-12 |
2016-06-16 |
Harvard College |
Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
|
|
CN105209621B
(zh)
|
2012-12-12 |
2021-05-25 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
KR102955556B1
(ko)
|
2012-12-12 |
2026-04-22 |
더 브로드 인스티튜트, 인코퍼레이티드 |
서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
JP6257655B2
(ja)
|
2013-03-01 |
2018-01-10 |
アメリカ合衆国 |
末梢血から腫瘍反応性ｔ細胞の濃縮された集団を作製する方法
|
|
WO2014133567A1
(en)
|
2013-03-01 |
2014-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing enriched populations of tumor-reactive t cells from tumor
|
|
RS57840B1
(sr)
|
2013-03-18 |
2018-12-31 |
Biocerox Prod Bv |
Humanizovana anti-cd 134 (ox40) antitela i njihove upotrebe
|
|
US11311575B2
(en)
|
2013-05-13 |
2022-04-26 |
Cellectis |
Methods for engineering highly active T cell for immunotherapy
|
|
CA2912375C
(en)
|
2013-05-13 |
2023-03-14 |
Cellectis |
Methods for engineering highly active t cell for immunotherapy
|
|
EP3004339B1
(en)
|
2013-05-29 |
2021-07-07 |
Cellectis |
New compact scaffold of cas9 in the type ii crispr system
|
|
SG10201705494YA
(en)
|
2013-06-24 |
2017-08-30 |
Wolf Wilson Mfg Corp |
Closed system device and methods for gas permeable cell culture process
|
|
CN105452448B
(zh)
|
2013-07-15 |
2020-07-28 |
美国卫生和人力服务部 |
制备抗人乳头瘤病毒抗原的t细胞的方法
|
|
WO2015039100A1
(en)
|
2013-09-16 |
2015-03-19 |
The Trustees Of The University Of Pennsylvania |
Cd137 enrichment for efficient tumor infiltrating lymphocyte selection
|
|
JP6976058B2
(ja)
|
2013-11-22 |
2021-12-01 |
セレクティスCellectis |
免疫療法のための化学療法薬耐性ｔ細胞を工学的に作製する方法
|
|
MX2016007965A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1.
|
|
US10899840B2
(en)
|
2014-02-04 |
2021-01-26 |
Pfizer Inc. |
Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
|
|
LT3105328T
(lt)
|
2014-02-11 |
2020-07-10 |
The Regents Of The University Of Colorado, A Body Corporate |
Daugiakomponentis genomo konstravimas, sudarantis sąlygas crispr
|
|
RU2752933C2
(ru)
|
2014-03-11 |
2021-08-11 |
Селлектис |
Способ создания т-клеток, пригодных для аллогенной трансплантации
|
|
EP3698850A1
(en)
|
2014-03-20 |
2020-08-26 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Tumor-infiltrating lymphocytes for adoptive cell therapy
|
|
ES2980788T3
(es)
|
2014-04-10 |
2024-10-03 |
H Lee Moffitt Cancer Ct & Res |
Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
|
|
CN106456670B
(zh)
*
|
2014-04-25 |
2020-01-07 |
蓝鸟生物公司 |
制备过继性细胞疗法的改善方法
|
|
UA123821C2
(uk)
|
2014-06-11 |
2021-06-09 |
Полібіосепт Гмбх |
Композиція для експансії лімфоцитів in vitro
|
|
EP4270006A3
(en)
|
2014-06-13 |
2024-01-10 |
Immudex ApS |
General detection and isolation of specific cells by binding of labeled molecules
|
|
ES2924709T3
(es)
|
2014-10-02 |
2022-10-10 |
Us Health |
Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
|
|
EP3034092A1
(en)
|
2014-12-17 |
2016-06-22 |
Université de Lausanne |
Adoptive immunotherapy for treating cancer
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
FR3040396A1
(fr)
|
2015-06-30 |
2017-03-03 |
Chu Nantes |
Procede de cryoconservation de lymphocytes infiltrant la tumeur
|
|
US20170152506A1
(en)
|
2015-08-28 |
2017-06-01 |
Batu Biologics, Inc. |
Inactivation of lymphocyte immunological checkpoints by gene editing
|
|
WO2017087784A1
(en)
*
|
2015-11-18 |
2017-05-26 |
Duke University |
Tumor infiltrating lymphocytes for treatment of cancer
|
|
EP4166161B1
(en)
|
2016-04-14 |
2026-03-04 |
Fred Hutchinson Cancer Center |
Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
|
|
MX2019002946A
(es)
|
2016-09-14 |
2019-09-26 |
Abbvie Biotherapeutics Inc |
Anticuerpos anti-pd-1 y sus usos.
|
|
EP4338799A3
(en)
*
|
2016-10-18 |
2024-06-05 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
CN110099998A
(zh)
|
2016-10-26 |
2019-08-06 |
艾欧凡斯生物治疗公司 |
冷冻保存的肿瘤浸润淋巴细胞的再刺激
|
|
EP3532075A4
(en)
*
|
2016-10-27 |
2020-07-08 |
Intima Bioscience, Inc. |
VIRAL METHODS OF MANUFACTURING GENETICALLY MODIFIED CELLS
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
GB201620415D0
(en)
|
2016-12-01 |
2017-01-18 |
Element Six Tech Ltd |
Single crystal synthetic diamond material via chemical vapour deposition
|
|
AU2018205234B2
(en)
|
2017-01-06 |
2024-09-19 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (TILs) with tumor necrosis factor receptor superfamily (TNFRSF) agonists and therapeutic combinations of TILs and TNFRSF agonists
|
|
ES3055314T3
(en)
|
2017-01-06 |
2026-02-11 |
Iovance Biotherapeutics Inc |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
CN110537266B
(zh)
|
2017-04-20 |
2022-06-17 |
大日本印刷株式会社 |
电池用包装材料、其制造方法以及电池
|
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
TW201919662A
(zh)
|
2017-06-05 |
2019-06-01 |
美商艾歐凡斯生物治療公司 |
對雙重難治性黑色素瘤使用腫瘤浸潤性淋巴細胞之方法
|
|
US12453697B2
(en)
*
|
2018-11-05 |
2025-10-28 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|